EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY 4.0

Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Muhammad Farhan iD, Muhammad Murtaza iD, Muhammad Mujtaba Rasool iD, Farah Khan iD, Hammad Amjad iD, Kuldeep Dalpat Rai iD, Sheikh Muhammad Ebtehaj Ali iD, Ahmed Asad Raza iD, Muhammad Ahmad Sohail iD, Abedin Samadi iD, Furqan Hassan iD

Endocrinology, Diabetes & Metabolism · 2026

DOI: 10.1002/edm2.70358 ↗

At a glance

Systematische Übersicht in Endocrinology, Diabetes & Metabolism, 2026. Written by Muhammad Farhan and 10 co-authors. Institution: Karachi Medical and Dental College, Karachi, Pakistan. Major MEDLINE topics: Hypercholesterolemia, PCSK9 Inhibitors, Anticholesteremic Agents. 37 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Atherosclerotic cardiovascular disease remains a leading cause of global mortality, with low‐density lipoprotein cholesterol (LDL‐C) reduction being the cornerstone of prevention. Despite effective therapies, many high‐risk patients do not achieve recommended LDL‐C targets. Enlicitide (MK‐0616), an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, offers a potential alternative to injectable PCSK9‐directed therapies.

Objective

To evaluate the efficacy and safety of enlicitide in adults with hypercholesterolemia and assess its dose‐dependent effects on lipid parameters.

Methods

We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) according to PRISMA 2020 guidelines. PubMed, Embase, Scopus, ClinicalTrials.gov, and Google Scholar were searched from inception through March 2026. Random‐effects meta‐analysis using restricted maximum likelihood estimation was performed. The primary outcome was the percentage change in LDL‐C from baseline. Secondary outcomes included non‐high‐density lipoprotein cholesterol (non‐HDL‐C), apolipoprotein B (ApoB), lipoprotein(a), triglycerides, and safety outcomes. Risk of bias and certainty of evidence were assessed using RoB 2.0 and GRADE.

Results

Three placebo‐controlled RCTs involving 3593 participants were included. Enlicitide significantly reduced LDL‐C compared with placebo (mean difference [MD], −56.19%; 95% CI, −64.14 to −48.25; p < 0.0001), with moderate heterogeneity ( I 2 = 56.9%). Significant reductions were also observed in non‐HDL‐C (MD, −51.36%), ApoB (MD, −47.09%), lipoprotein(a) (MD, −20.10%), and triglycerides (MD, −13.12%). A numerical dose–response gradient was observed, although subgroup differences were not statistically significant. Sensitivity analyses supported the robustness of the findings. Rates of adverse events, serious adverse events, and treatment discontinuation were comparable between groups.

Conclusion

Enlicitide produced substantial reductions in LDL‐C and other atherogenic lipid parameters without an apparent increase in adverse events. However, findings should be interpreted cautiously given the limited number of trials, moderate heterogeneity, and reliance on surrogate endpoints. Dose–response, duration‐related lipoprotein(a), and triglyceride findings were exploratory and substantially driven by single trials. Long‐term cardiovascular outcomes trials are needed to establish clinical benefit.

Subjects

MeSH terms (MEDLINE)

HypercholesterolemiaPCSK9 InhibitorsAnticholesteremic AgentsHumansRandomized Controlled Trials as TopicCholesterol, LDLTreatment OutcomeProprotein Convertase 9

Author keywords

LDL cholesterolMK‐0616PCSK9 inhibitorenlicitidehypercholesterolemiameta‐analysis

Substances

Cholesterol, LDLPCSK9 InhibitorsAnticholesteremic AgentsPCSK9 protein, humanProprotein Convertase 9

Authors and institutions

  • Karachi Medical and Dental College, Karachi, Pakistan.
  • Services Institute of Medical Sciences, Lahore, Pakistan.
  • Allama Iqbal Medical College, Lahore, Pakistan.
  • Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Medicine, Abbasi Shaheed Hospital, Karachi, Pakistan.
  • Jinnah Sindh Medical University, Karachi, Pakistan.

ORCID profiles: Muhammad Farhan, Muhammad Murtaza, Muhammad Mujtaba Rasool, Farah Khan, Hammad Amjad, Kuldeep Dalpat Rai, Sheikh Muhammad Ebtehaj Ali, Ahmed Asad Raza, Muhammad Ahmad Sohail, Abedin Samadi, Furqan Hassan

Cite

APA

Farhan, M., Murtaza, M., Rasool, M. M., Khan, F., Amjad, H., Rai, K. D., Ali, S. M. E., Raza, A. A., Sohail, M. A., Samadi, A., & Hassan, F. (2026). Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70358

Vancouver

Farhan M, Murtaza M, Rasool MM, Khan F, Amjad H, Rai KD, et al. Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70358

BibTeX
@article{Farhan2026,
  author = {Farhan, Muhammad and Murtaza, Muhammad and Rasool, Muhammad Mujtaba and Khan, Farah and Amjad, Hammad and Rai, Kuldeep Dalpat and Ali, Sheikh Muhammad Ebtehaj and Raza, Ahmed Asad and Sohail, Muhammad Ahmad and Samadi, Abedin and Hassan, Furqan},
  title = {Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  doi = {10.1002/edm2.70358}
}
Start for free →